Results 231 to 240 of about 58,375 (292)

IL-33 as a Marker of Poor Early Response in Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. [PDF]

open access: yesInt J Mol Sci
Vuleta Nedic K   +9 more
europepmc   +1 more source

Targeted radionuclide therapy for gliomas: Emerging clinical trial landscape. [PDF]

open access: yesNeuro Oncol
Weller M   +9 more
europepmc   +1 more source

Targeted radionuclide therapy for patients with central nervous system metastasis: Overlooked potential? [PDF]

open access: yesNeuro Oncol
Le Rhun E   +10 more
europepmc   +1 more source

Supplementary Figure S.8 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers

open access: gold
Maxim Kuznetsov   +6 more
openalex   +1 more source

SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors. [PDF]

open access: yesEur J Nucl Med Mol Imaging
Hasenauer N   +9 more
europepmc   +1 more source

Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE and Monitoring with Somatostatin Receptor PET/CT in Patients with Advanced Differentiated Thyroid Carcinoma. [PDF]

open access: yesMol Imaging Biol
Kunte SC   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy